Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
A052 Nirsevimab Biosimilar (Anti-RSV Reference Antibody) Featured Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections.
A053 Aselizumab Biosimilar (Anti-L-selectin Reference Antibody) Featured Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma.
A054 Raxibacumab Biosimilar(Anti-PA Reference Antibody) Featured Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research.
A055 Afelimomab Biosimilar (Anti-TNFSF2 / TNFa Reference Antibody) Featured Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis.
A056 Agensys patent anti-158P1D7 Biosimilar (Anti-158P1D7 Reference Antibody) Featured
A057 Numab patent anti-HSA Biosimilar(Anti-Albumin Reference Antibody) Featured
A058 Birtamimab Biosimilar (Anti-Amyloid Alpha Reference Antibody) Featured Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis.
A059 Mirzotamab Biosimilar (Anti-B7-H3 / CD276 Reference Antibody) Featured Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).
A060 Cantuzumab Biosimilar (Anti-CanAg Reference Antibody) Featured Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493).
A061 VLST-002 Biosimilar (Anti-CCL5 / RANTES Reference Antibody) Featured
A062 R707 Biosimilar (Anti-CCR7 / CD197 Reference Antibody) Featured
A063 Ofatumumab Biosimilar (Anti-CD20 Reference Antibody) Featured Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.
A064 Genefrontier patent anti-CD69 Biosimilar (Anti-CD69 Reference Antibody) Featured
A065 KHK-2898 Biosimilar (Anti-CD98 Reference Antibody) Featured
A066 CergutuzumAb Biosimilar (Anti-CEACAM5 / CEA / CD66e Reference Antibody) Featured
A067 Immunomedics patent anti-CEACAM5 (Class III) Biosimilar (Anti-CEACAM5 / CEA / CD66e Reference Antibody) Featured
A068 IMAB027 Biosimilar (Anti-CLDN6 Reference Antibody) Featured IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6+ ovarian and testicular cancer cell lines.
A069 AB1-11 Biosimilar (Anti-CLDN6 Reference Antibody) Featured
A070 IM-301 Biosimilar (Anti-CLDN6 Reference Antibody) Featured
A071 lendalizumab Biosimilar (Anti-Complement C5 Reference Antibody) Featured
A072 Nurulimab Biosimilar (Anti-CTLA-4 / CD152 Reference Antibody) Featured Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma.
DC66645 Epilactose Featured
DC66646 Dinotefuran UF Featured Dinotefuran UF is the deuterium labeled γ-Tocotrienol. γ-Tocotrienol is an active form of vitamin E
DC66647 ICA-1S Featured ICA-1S is a potent, specific inhibitor of Protein Kinase C-iota (PKC-ι), does not inhibit PKC-ζ, the closely related atypical PKC family member.
DC60638 Acid-degradable PEG Lipid (ADP-2k) Featured Acid-degradable PEG Lipid (ADP) composed of polyethylene glycol lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.
DC60639 Acid-degradable Anionic Lipid (ADA) Featured Acid-degradable Anionic Lipid (ADA) composed of anionic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.
DC60640 LI-3948 Featured LI-3948 is a blood-brain barrier penetrant inositol hexakisphosphate kinase (IP6K) inhibitor with IC50 of 16 nM and brain/plasma ratio of 1.3, respectively.
DC66648 CP-LC-1143 Featured Lipid CP-LC-1143 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.
DC66651 CP-LC-0743 Featured Lipid CP-LC-0743 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.
A073 Antitope patent anti-CTLA4 Biosimilar (Anti-CTLA-4 / CD152 Reference Antibody) Featured

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>